The Peptide Audit

What is PT-141?

Approved drugReproductive research · Last reviewed September 28, 2026

PT-141 (bremelanotide) is a synthetic peptide derived from melanotan-2.

How does PT-141 work?

It activates melanocortin receptors in the brain (mainly MC4R) that are involved in sexual arousal pathways, rather than acting on blood flow.

What are researchers studying?

Where does the evidence stand?

Approved drug

FDA-approved in 2019 (Vyleesi) for premenopausal women with hypoactive sexual desire disorder.

Quick facts

Research area
Reproductive
Also known as
Bremelanotide, PT141
Third-party lab results
4 published COAs →
Tested vendors tracking it
2 vendors →

Recent peer-reviewed research

The most relevant PT-141 studies from the last three years, via PubMed (U.S. National Library of Medicine).

  1. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
    International journal of molecular sciences · 2026 Apr 27 · PubMed ↗
  2. Bremelanotide
    · 2006 · PubMed ↗
  3. Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions
    Expert opinion on pharmacotherapy · 2025 Apr · PubMed ↗

Compare PT-141

Related research guides

Free weekly email
Get The Peptide Audit Weekly

Every Monday: the week's price drops and restocks, new third-party lab results, and a plain-English research guide with the latest studies. No spam — unsubscribe anytime.

This guide summarizes published research for educational purposes only. It is not medical advice and does not describe how to use PT-141. Citations link to PubMed and are listed for reference — we haven't reviewed or endorsed their findings. Products referenced on The Peptide Audit are sold by third parties for laboratory research use only and are not for human consumption.